Jump to content
Powered by

Boehringer-reduced operating income

High research expenditures along with a strong Euro have curbed Boehringer Ingelheim’s revenues in the first six months of 2008. The company has increased its sales revenues to 5.52 billion euros, which after consolidation in euro, was +2.1%. The company's operating income of 900 million euros decreased by about 10% to 899 million euros.

Boehringer Ingelheim expects continued sales growth, stronger than the world pharmaceutical market, as well as an improvement of the operating income. In 2007, the company achieved sales revenues of 10.95 billion euros and an operating income of 2.1 billion euros.

Blockbusters gain further

In the first six months of 2008, net sales in the core business Prescription Medicines increased by 8.5%, in local currencies, up to 4.35 billion euros. International key brands account for 76% of the net sales in the Prescription Medicines business, including Spiriva®, which is for the treatment of chronic obstructive pulmonary disease (976 million euros, up 23.8%), Micardis®, a cardiovascular product for the treatment of high blood pressure (603 million euros, up 11.5%), and Flomax®/Alna® (496 million euros, up 7.3%) for the treatment of benign prostatic hyperplasia.

Thrombin inhibitor introduced to several companies

Boehringer Ingelheim was quite pleased about their research and development. Pradaxa® (dabigatran etexilate), which is an innovative oral direct thrombin inhibitor, has now been introduced in Northern Europe, Canada and New Zealand, just after Germany and the United Kingdom. The drug was approved for the prevention of venous thromboembolic disorders following hip or knee replacement surgery in adults. Further studies on additional indications are making good progress and recruitment has begun for a clinical phase II programme in acute coronary artery disease.

Diabetes-2 compound in phase III

The data of flibanserin phase III studies for the indication of hypoactive female sexual desire disorder are currently being analysed. All phase III studies required for the registration of the antidiabetic compound BI1356 (ONDERO®) in the indication diabetes mellitus type 2 have now started worldwide. According to the company’s information, all the studies are expected to be completed on time. Similarly, good progress has been made on the preparation and introduction of the phase III studies with the two oncology compounds BIBW 2992 (TOVOK®) and BIBF 1120 (VARGATEF®).

Source: Boehringer Ingelheim press release - 7 August 2008 (P, wp, 19 August 2008)
Website address: https://www.gesundheitsindustrie-bw.de/en/article/press-release/boehringer-reduced-operating-income